Dec-07 -

Brain Group

EORTC 26951 – Phase III study of adjuvant Procarbazine, CCNU and Vincristine chemotherapy in patients with highly anaplastic oligodendroglioma (randomized).

EORTC study assessing the effectiveness of the combination treatment of chemotherapy (PCV) and radiotherapy in patients with anaplastic oligodendroglioma (a rare brain tumour). Results show that this combination treatment slightly improves progression free survival but negatively impact patients’ health-related quality of life (HRQOL) scores. This result provided more insight into the potential benefit of early, aggressive treatment.


Go to Top